Data of InnoCare s robust pipelines were presented at the European Hematology Association 2024 Hybrid Congress.
1. Subcutaneous ICP-B02 , a Novel Bispecific CD20/CD3 Antibody Showed Promising.
More than 20 abstracts will be presented from clinical trials and real-world evidence using clonoSEQ for MRD assessment across multiple types of blood cancersSEATTLE, May 31, 2024 Adaptive.
Adaptive Biotechnologies Announces Data Supporting the globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
RYBREVANT®▼ (amivantamab) plus lazertinib shows longer globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Johnson & Johnson Submits Application To The European Medicines Agency Seeking Approval Of Subcutaneous Formulation Of RYBREVANT®▼ (Amivantamab) For T... menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.